Acacia pockets £16m from partial sale of former Woodford Oxford Nanopore stake
Share sale combined with value of US investor’s remaining stake represents a 78% uplift on biotech firm’s last valuation
Share sale combined with value of US investor’s remaining stake represents a 78% uplift on biotech firm’s last valuation
|
|
Oxford Nanopore debuted at a price of 425p per share, netting SUPP £11m
|
|
Oxford Nanopore represented 21.8% of SUPP’s net asset value on 31 March
|
|
DNA sequencing unicorn reported a £73m pre-tax loss in 2020 despite revenue boost from government contracts for Covid tests
|
|
University of Oxford spin-out makes up chunky weighting of Neil Woodford’s comeback fund
|
|
DNA sequencing start-up among bundle of stocks sold to Acacia Research in June last year
|
|
LF Equity Income has already ditched the unquoted company but Schroders trust set to benefit
|
|
Gene sequencing firm was worst-performing stock in Invesco High Income in Q1
|
|
California pharma giant invests in Oxford Nanopore
|
|